Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.
Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy. On March 27, 2020, durvalumab was approved by the FDA for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Durvalumab is indicated for the treatment of adults with the following conditions:
Research Site, Zhengzhou, China
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
Christiana Care Health Services, Newark, Delaware, United States
Henry Ford Health System, Detroit, Michigan, United States
Research Site, Morgantown, West Virginia, United States
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Research Site, Ho Chi Minh, Vietnam
Research Site, Ho Chi Minh, Vietnam
Tianjin Cancer Hospital ( Site 0329), Tianjin, Tianjin, China
Hangzhou Cancer Hospital-Medical Oncology ( Site 0302), Hangzhou, Zhejiang, China
The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301), Hangzhou, Zhejiang, China
Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Porto, Portugal
Assuta MC, Tel Aviv, Israel
The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
Medisch Spectrum Twente, Enschede, Netherlands
The MMRd-GREEN trial: Leiden University Medical Center, Leiden, Netherlands
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.